Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | PTPRF | P10586 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729507 | 0.97 | CHEK2 (0.46) | CHEK2PTGS2LTA4HESR1ESR2 | |
| SCHEMBL5729625 | 0.97 | CHEK2 (0.46) | CHEK2PTGS2LTA4HESR1ESR2 | |
| SCHEMBL5729282 | 0.92 | CHEK2 (0.49) | CHEK2PTGS2LTA4HESR1ESR2 | |
| SCHEMBL5731064 | 0.89 | CHEK2 (0.45) | CHEK2PTGS2LTA4HESR1ESR2 | |
| SCHEMBL5729577 | 0.88 | CHEK1 (0.42) | CHEK2PTGS2ESR1ESR2CHEK1 | |
| Hydrochloric Acid SCHEMBL6311273 | 0.87 | CHEK1 (0.42) | CHEK2PTGS2ESR1ESR2CHEK1 | |
| SCHEMBL6394083 | 0.85 | PTGS2 (0.47) | CHEK2PTGS2LTA4HCHEK1PTGS1 | |
| SCHEMBL5729300 | 0.85 | PTGS2 (0.47) | CHEK2PTGS2LTA4HCHEK1PTGS1 | |
| SCHEMBL6304487 | 0.85 | CHEK2 (0.46) | CHEK2PTGS2LTA4HESR1ESR2 | |
| SCHEMBL5729698 | 0.83 | CHEK2 (0.45) | CHEK2PTGS2LTA4HESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102755-B1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6869969-B2 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6743815-B2 | OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | CHIRON CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20030065012-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-20010036956-A1 | Estrogen receptor modulators | HUEBNER VERENA D (US) | 2001-11-01 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1102755-A1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008001-A1 | SUBSTITUTED ISOXAZOLE AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036956-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CHEK2 1773/4885PTGS2 728/4885LTA4H 886/4885 |
| US-20030065012-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CHEK2 1773/4885PTGS2 728/4885LTA4H 886/4885 |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | ESR2, GPER1, ESR1 | CHEK2 831/4885PTGS2 515/4885LTA4H 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.